Tuesday, October 4, 2022


Biotechnology News Magazine

Berkshire Biomedical Awarded NIH Research Grant

The Funds Will Be Used to Support Continued Development of the COPA™ System for Automated at Home Methadone Administration

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

Berkshire Biomedical Corporation (“Berkshire” or “the Company”), focused on developing its proprietary, hand-held, automated personalized drug dispensing technology to enhance patient wellness, today announced that it has been awarded the first phase of a two-phase Fast-Track Small Business Innovation Research (SBIR) grant (1R44DA057185-01) from the National Institutes of Health’s (NIH) National Institute of Drug Abuse (NIDA).

Valued at approximately $2.0 million over two years, the two-phase grant will support continued non-clinical development of the Company’s Computerized Oral Prescription Administration System (COPA™) for at home methadone administration as part of Medication for Opioid User Disorder (MOUD) treatment.

COPA is a novel oral liquid dispensing system with remote monitoring and advanced analytics specifically designed to deliver accurate and precise doses of controlled and non-controlled prescription medications to only a biometrically authenticated Intended User. Berkshire has been awarded Phase I funds of approximately $266,000. Receipt of the approximate $1.7 million Phase II award will be contingent on an assessment of the Phase I report, the review and approval of any other documentation necessary for continuation, and availability of funds.

“The Fast-Track SBIR grant process is highly competitive, with only 15% of applicants having been chosen under this program in 2021. Berkshire’s receipt of this award reflects the NIH’s belief in the strength of the technology behind COPA and its potential to significantly increase access to Opioid Treatment Programs for persons suffering from Opioid Use Disorder (OUD) by dramatically increasing the number of persons being allowed to utilize take home therapy,” stated John Timberlake, Chief Executive Officer of Berkshire.

Mr. Timberlake continued, “Prior to the COVID-19 epidemic, there was a serious unmet need to support OUD patients. Now there is an even greater critical need for a system capable of accurately and securely dispensing methadone for at home use that incorporates real-time remote monitoring, as the pandemic has limited access to methadone maintenance treatment (MMT) programs in both urban and rural sections of the U.S. That said, with assistance from this initial Phase I SBIR grant and the subsequent Phase II award, our goal is to complete the development of our enhancements to COPA, complete all necessary device, system, and human factors testing, followed by the subsequent submission of our De Novo request for review by the U.S. Food and Drug Administration (FDA).”

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine